Adjacent Evidence Brief: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add a clear, specific research question that can be directly answered by the evidence (e.g., 'In cancer populations, does shorter LTL predict survival, and does genetically predicted longer LTL increase cancer risk across tumor types?').
2. Reclassify misclassified sources: move Liu 2026 out of dosing/pharmacokinetics (it is an epigenetic age acceleration study, not a PK study); move Markozannes 2022 out of immune/inflammation (it is a cancer MR systematic review); re-examine Brouwers 2016 direction coding given the bundle reports comparable LTL decline in both arms.
3. Resolve or transparently disclose the 17/25 'unclear' effect_direction codes — either re-extract directional findings from the source excerpts or clearly state that the synthesis cannot determine direction for the majority of the corpus and narrow the conclusion accordingly.
4. Integrate the evidence across outcome classes: explicitly contrast MR risk findings (longer LTL → higher risk for glioma, melanoma, prostate, lymphoid, etc.) against prognostic biomarker findings (shorter LTL → worse survival in breast/CRC) and mechanistic ALT findings, to actually test the direction-dependence thesis stated in the abstract.
5. Either remove or explicitly segregate off-topic sources (Jaeger 2024 Astragalus RCT in healthy volunteers, Brouwers 2016 frailty-adjacent endpoint, Liang 2024 HIV-focused longevity analysis) from the telomere-cancer evidence map, or add a clear 'adjacent context' label with explicit non-pooling rationale.
6. Reconcile the receipt funnel arithmetic and add a one-sentence interpretation of why the admission funnel yielded 25 sources from 73 candidates.
7. Narrow the Conclusion to what the 25 sources can actually support: currently the Conclusion makes structural claims (evidence hierarchy, tiered reading, tiered translational weight) that go beyond what is synthesized in the body.

Major issues

• The research question is framed vaguely as 'what does the retained source corpus establish about Telomere Cancer Effects' — this is a corpus-mapping question, not a specific scientific question, so it cannot be directly answered with bounded findings.
• The synthesis reads as a catalog of source-level statistics grouped by outcome class rather than an integrated argument; there is no synthesis across evidence classes (e.g., MR risk findings vs. prognostic biomarker findings vs. mechanistic ALT findings) to support the thesis that telomere-cancer effects are context-dependent and direction-dependent.
• 17 of 25 sources are coded with effect_direction='unclear', which is a data-extraction failure rather than a substantive finding; the manuscript acknowledges this but does not resolve it, leaving the conclusion unable to distinguish true null/positive effects from extraction gaps.
• The conclusion overstates what was synthesized: it claims the paper 'tests the thesis that evidence is context-dependent' but the body never formally tests that thesis — it lists outcome packets without integration.
• Several cited sources are misclassified or mislabeled: Liu 2026 is coded under 'dosing and pharmacokinetics' but is an epigenetic age acceleration study in smokers; Brouwers 2016 is coded positive in the Frailty table but the bundle excerpt reports null LTL effect with only minor biomarker changes; Markozannes 2022 is under 'Immune and Inflammation' but is an MR cancer-risk systematic review.
• The abstract claims the synthesis tests a thesis and tests that telomere-cancer relationships are 'direction-dependent rather than unitary', but the Conclusion section never operationalizes or tests direction-dependence; it is asserted rather than demonstrated.

Minor issues

• The receipt funnel numbers don't sum cleanly: 48 + 20 + 7 + 3 = 78 vs. the 73 classified source candidates and 25 admitted sources — the funnel logic needs clearer explanation.
• Several 2026-dated sources appear in the bundle (Liu 2026, Li 2026, Davidson-Swinton 2026, Langsenlehner 2026, Gil-Korilis 2026, Cheng 2026, Sarkar 2026, Genetta 2026, Brown 2026, Aierken 2026, Afolabi 2026, Alqaisi 2026) which may reflect forthcoming/in-press publications and should be flagged or verified.
• The 'causal-risk and Mendelian-randomization evidence n=7' count in the Conclusion is not broken out in the evidence landscape tables, reducing auditability.
• Jaeger 2024 (Astragalus supplement RCT, n=40) is bundled alongside cancer-effect sources but is not a cancer-population study — it should be explicitly flagged as off-topic or excluded from the telomere-cancer synthesis.
• The 'Evidence Landscape' table reports 'claims=473' for the contextual slice but the manuscript never integrates these claims into a substantive finding.

Reviewer note

This rapid evidence synthesis attempts to map 25 sources on telomere-cancer effects across multiple outcome classes and concludes that evidence is context-dependent and direction-dependent. The source bundle is well-curated: DOIs are real, sources are recent (mostly 2022–2026), and the included studies do broadly address telomere-cancer relationships across MR risk studies, prognostic biomarker cohorts, and mechanistic work. Source grounding is therefore strong. However, several substantive problems push this toward revise rather than accept. First, the research question is corpus-mapping rather than scientific, so the manuscript cannot be judged to have 'directly answered' a specific question. Second, the body is structured as a catalog of outcome-class tables and source-level bullet lists rather than an integrated synthesis — there is no explicit cross-class argument that would test the direction-dependence thesis asserted in the abstract. Third, 17 of 25 sources carry effect_direction='unclear', which is treated as a finding but is actually an extraction gap; the manuscript does not resolve this and instead builds the conclusion on top of it. Fourth, several sources are misclassified into outcome classes (Liu 2026 as dosing/PK, Markozannes 2022 as immune/inflammation, Brouwers 2016 direction coded positive despite bundle reporting null LTL effect), which undermines the structured synthesis. Fifth, off-topic or off-population sources (Jaeger 2024 healthy-volunteer Astragalus RCT; Liang 2024 HIV-focused longevity study) are folded into the telomere-cancer evidence map without clear segregation. The conclusion is appropriately hedged and explicitly disclaims clinical/policy translation, which is a strength. But the Conclusion makes structural claims about evidence hierarchy and tiered translational weight that are not earned by the body synthesis. With the specific revisions listed — particularly integrating MR vs. prognostic vs. mechanistic evidence to actually test direction-dependence, resolving the unclear-direction codes, and reclassifying misassigned sources — the manuscript could become a competent bounded synthesis. In current form, it reads more like a structured evidence audit than a synthesis, and therefore warrants revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis